HK91993A - Compositions containing prostaglandins - Google Patents

Compositions containing prostaglandins Download PDF

Info

Publication number
HK91993A
HK91993A HK919/93A HK91993A HK91993A HK 91993 A HK91993 A HK 91993A HK 919/93 A HK919/93 A HK 919/93A HK 91993 A HK91993 A HK 91993A HK 91993 A HK91993 A HK 91993A
Authority
HK
Hong Kong
Prior art keywords
pge
gels
composition according
compound
gel
Prior art date
Application number
HK919/93A
Other languages
German (de)
English (en)
Inventor
Brian Samuel Johnson
Original Assignee
Upjohn Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Limited filed Critical Upjohn Limited
Publication of HK91993A publication Critical patent/HK91993A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (10)

1. Composition acceptable du point de vue pharmaceutique, sous la forme d'un gel s'écoulant librement, qui comprend un composé du type PGE, du dioxyde de silicium colloïdal et un liquide organique stabilisant.
2. Composition suivant la revendication 1, dans laquelle le liquide organique est un ester de glycéryle.
3. Composition suivant la revendication 2, dans laquelle l'ester de glycéryle est la triacétine.
4. Composition suivant la revendication 2, qui comprend 8 à 15% en poids de dioxyde de silicium colloïdal.
5. Composition suivant l'une quelconque des revendications 1 à 4, dans laquelle le composé PGE consiste en PGE2.
6. Compositions suivant l'une quelconque des revendications 1 à 4, dans laquelle le composé PGE consiste en (15R)-15-méthyl-PGE2.
7. Composition suivant l'une quelconque des revendications 1 à 4, dans laquelle le composé PGE consiste en 16,16-diméthyl-PGE2.
8. Composition suivant l'une quelconque des revendications 1 à 4, dans laquelle le composé PGE consiste en (17S),20-diméthyl-PGE2.
9. Composition suivant l'une quelconque des revendications 1 à 4, dans laquelle le composé PGE consiste en 15-méthyl-PGE2.
10. Composition suivant l'une quelconque des revendications 1 à 4, dans laquelle le composé PGE consiste en PGE,.
HK919/93A 1982-03-22 1993-09-02 Compositions containing prostaglandins HK91993A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8208322 1982-03-22

Publications (1)

Publication Number Publication Date
HK91993A true HK91993A (en) 1993-09-10

Family

ID=10529176

Family Applications (1)

Application Number Title Priority Date Filing Date
HK919/93A HK91993A (en) 1982-03-22 1993-09-02 Compositions containing prostaglandins

Country Status (9)

Country Link
US (1) US4680312A (fr)
EP (1) EP0089768B1 (fr)
JP (1) JPS58167509A (fr)
DE (1) DE3381898D1 (fr)
DK (1) DK167139B1 (fr)
FI (1) FI81962C (fr)
HK (1) HK91993A (fr)
NO (1) NO163042C (fr)
ZA (1) ZA831186B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277622A (ja) * 1985-05-31 1986-12-08 Teijin Ltd 活性型ビタミンｄ３類製剤用組成物
ES2107051T3 (es) * 1992-09-21 1997-11-16 Upjohn Co Formulaciones de proteinas de liberacion sostenida.
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
CA2295595A1 (fr) 1997-07-09 1999-01-21 Androsolutions, Inc. Compositions et procedes perfectionnes de traitement des troubles de l'erection chez l'homme
US6593369B2 (en) 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
CA2306837C (fr) 1997-10-28 2007-05-08 Vivus, Inc. Traitement du dysfonctionnement sexuel chez la femme
US20020009478A1 (en) * 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
RU2223101C2 (ru) * 2001-10-04 2004-02-10 Санкт-Петербургская Государственная Химико-Фармацевтическая Академия Набор для стимуляции родовой деятельности
BR112013025070A2 (pt) * 2011-03-31 2017-02-14 Fujifilm Corp emulsão graxa contendo prostaglandina
AU2014220339B2 (en) 2013-02-25 2016-12-01 Sun Pharmaceutical Industries Limited Oral formulation and suspension of an oncology drug
AT515356B1 (de) * 2014-01-30 2015-11-15 Gebro Holding Gmbh Stabile alkoholische Lösung von Alprostadil
CN107496348A (zh) * 2017-08-28 2017-12-22 天津昂赛细胞基因工程有限公司 一种用于组织损伤修复的水凝胶及制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (fr) * 1970-06-10 1975-02-04
US3749800A (en) * 1971-11-01 1973-07-31 Upjohn Co Stable composition for dispensing pge2
US3829579A (en) * 1971-11-01 1974-08-13 Upjohn Co Stable solutions of pge-type compounds
US3826823A (en) * 1972-09-25 1974-07-30 Syntex Inc Stabilized prostaglandin preparations
US3927197A (en) * 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
JPS51136818A (en) * 1975-05-20 1976-11-26 Yamanouchi Pharmaceut Co Ltd Method for preparing stable prostaglandine pharma ceuticals
US3966962A (en) * 1975-03-27 1976-06-29 The Upjohn Company Triacetin solutions of PGE-type compounds
JPS6043335B2 (ja) * 1976-05-21 1985-09-27 山之内製薬株式会社 安定なプロスタグランジンｅ類含有組成物
SE431821B (sv) * 1979-01-29 1984-03-05 Perstorp Ab Lagringsstabilt, prostaglandininnehallande medicinskt preparat
US4211793A (en) * 1979-03-19 1980-07-08 American Cyanamid Company Triethyl citrate solutions of PGE-type compounds
NZ193221A (en) * 1979-03-21 1984-08-24 M P Embrey Controlled release composition
JPS6033429B2 (ja) * 1980-04-28 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
JPS6033430B2 (ja) * 1980-05-12 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物

Also Published As

Publication number Publication date
NO163042C (no) 1990-04-18
FI81962B (fi) 1990-09-28
EP0089768B1 (fr) 1990-09-26
NO830988L (no) 1983-09-23
DK127883D0 (da) 1983-03-21
FI81962C (fi) 1991-01-10
ZA831186B (en) 1983-11-30
FI830890L (fi) 1983-09-23
EP0089768A1 (fr) 1983-09-28
JPS58167509A (ja) 1983-10-03
NO163042B (no) 1989-12-18
JPH0322850B2 (fr) 1991-03-27
US4680312A (en) 1987-07-14
DK127883A (da) 1983-09-23
FI830890A0 (fi) 1983-03-17
DK167139B1 (da) 1993-09-06
DE3381898D1 (de) 1990-10-31

Similar Documents

Publication Publication Date Title
EP0089768B1 (fr) Compositions contenant des prostaglandines
US4888168A (en) Stable ophthalmic preparations containing acetazolamide
US4889845A (en) Vehicle for topical application of pharmaceuticals
US2703777A (en) Ophthalmological preparations and vehicles and method of making the same
KR100634571B1 (ko) 연질 젤라틴 제제용 약학 조성물의 제조 방법
EP0390369A2 (fr) Compositions administrables par voie orale contenant de l'ibuprofène
JPS62190119A (ja) 高粘度ヒドロゲル又は懸濁液を得るための製剤
EP0357030B1 (fr) Utilisation des antagonistes du récepteur de thromboxane A2 pour la préparation d'une composition pharmaceutique pour le traitement des troubles de la peau
JPH10511364A (ja) 安定なブデゾナイド溶液、その製造方法並びに該溶液を浣腸剤及び医薬泡沫剤として使用する用途
JPH02300114A (ja) 薬物送達組成物と外傷包帯組成物
JPH0140013B2 (fr)
JPH06501710A (ja) ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤
US4923862A (en) Topical preparation containing ofloxacin
EP0719548A1 (fr) Agent gélifiant pour le polyéthylène glycol
HU189736B (en) New suppository base ensuring steady active substance release
KR100196212B1 (ko) 니코란딜을 함유하는 안정한 약제조성물
US5378470A (en) Rectally administered pharmaceutical preparation
JP2011241211A (ja) コルチコステロイドを含有するスティックタイプの局所製剤
PT706380E (pt) Farmaco encapsulado
US2637679A (en) Intramuscularly-administrable prolonged-action penicillin products
CA1249223A (fr) Formulations de medicaments solides et suspensions stables
CZ277775B6 (en) Process for preparing ethopside agent
CA1180276A (fr) Solutions d pge.sub.2/triacetine gelifiees
US3325366A (en) Biologically absorbable foam packing bandage and process therefor
EP0436015B1 (fr) Preparation pharmaceutique pour administration rectale

Legal Events

Date Code Title Description
PE Patent expired